Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers ...

Orna Therapeutics, which engineers immune cells inside the body, will fold into one of the world’s largest drugmakers. The post Eli Lilly snaps up Watertown biotech in $2.4 billion deal appeared first ...

By Padmanabhan Ananthan and Sriparna Roy Feb 9 (Reuters) - Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...

SHANGHAI, Feb 11 (Reuters) - Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel ...

This history of rapid acceleration suggests that Eli Lilly is primed for another massive breakout as new catalysts emerge.

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. | Eli Lilly ...

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion ...

The stock price has climbed in the triple digits over three years.